menu
    • menu

    Company profile for Modus Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical needs. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. Modus' largest owners are Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (jointly owned by Karolinska Development AB and Rosetta Capital), and John Öhd. The company has bee...
    Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical needs. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. Modus' largest owners are Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (jointly owned by Karolinska Development AB and Rosetta Capital), and John Öhd. The company has been listed on the Nasdaq First North Growth Market since July 2021.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Modus TherapeuticsSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Olof Palmes gata 29 IV, 11122 Stockholm
    Telephone
    Telephone
    +468 502 492 53
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.modustx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/modus-therapeutics-holding-ab/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Modus Therapeutics Initiates Phase 2A Study For Anemia
    Modus Therapeutics Initiates Phase 2A Study For Anemia

    10 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-10/first-patient-dosed-in-part-2-of-modus-therapeutics-phase-iia-study-in-chronic-kidney-disease-with-anemia

    PHARMIWEB
    10 Dec 2025
    Share Share
    Modus Therapeutics Releases Q3 2025 Interim Report
    Modus Therapeutics Releases Q3 2025 Interim Report

    26 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-26/modus-therapeutics-publishes-interim-report-for-the-third-quarter-2025

    PHARMIWEB
    26 Nov 2025
    Share Share
    Modus Therapeutics Receives Approval for Ph IIa CKD Clinical Trial
    Modus Therapeutics Receives Approval for Ph IIa CKD Clinical Trial

    19 Nov 2024

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2024-11-19/modus-therapeutics-receives-approval-to-initiate-a-phase-iia-clinical-trial-for-chronic-kidney-disease-ckd

    PHARMAWEB
    19 Nov 2024
    Share Share
    Modus mulls Phase II trials of sevuparin in anaemia
    Modus mulls Phase II trials of sevuparin in anaemia

    13 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/modus-mulls-phase-ii-trials-of-sevuparin-in-anaemia/

    CLINICAL TRIALS ARENA
    13 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search